SPOTLIGHT: Bayer: Nexavar boosts blood pressure


Bayer and Onyx Pharmaceuticals defended Nexavar against a new Lancet article that concludes the cancer drug causes high blood pressure; the companies say that risk is already highlighted on the product's label. Report | Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.